Birth in the Neonatal HBV Vaccination Era and Hepatitis B Surface Antigen Seroclearance in People With HIV-1 and HBV Coinfection on Tenofovir-containing Antiretroviral Therapy
Clinical Infectious Diseases · 11.07.2026
DOI: 10.1093/cid/ciag429 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 11.07.2026. Verfasst von Yu-Shan Huang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Hauptthemen laut MEDLINE: Tenofovir, HIV Infections, Hepatitis B Surface Antigens, Coinfection. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The impact of long-term tenofovir-containing antiretroviral therapy (ART) on hepatitis B surface antigen (HBsAg) seroclearance in people with HIV-1 (PWH) and HBV coinfection remains under-defined, particularly in HBV-hyperendemic regions with universal neonatal vaccination programs.
Methods
HBsAg-positive PWH receiving tenofovir-containing ART between 2011 and 2023 were followed until December 2025. Demographics, HBV serologic markers, plasma HBV DNA, and liver fibrosis stage were collected. Cox proportional hazards models were used to identify factors associated with HBsAg seroclearance. Clinical and hepatic outcomes were compared with seroclearance status.
Results
After a median follow-up of 9.4 years, 35 (8.4%) of 415 PWH achieved HBsAg seroclearance during a total of 3600 person-years of tenofovir-containing ART, corresponding to an incidence rate of 0.97 per 100 person-years. Among them, 37.1% (13/35) tested positive for anti-HBs at the time of seroclearance. In multivariable analysis, birth in universal neonatal HBV vaccination era (after July 1986) (adjusted hazard ratio [aHR] 13.56, 95% confidence interval [CI] 6.08–30.28, P < .001), baseline HBsAg ≤250 IU/mL (aHR 7.36, 95% CI 3.29–16.50, P < .001), and higher baseline ALT level (aHR 1.00 per 1-U/L increase, 95% CI 1.00–1.01, P < .001) were independently associated with HBsAg seroclearance. None of PWH who achieved HBsAg seroclearance developed seroreversion, cirrhosis, or hepatocellular carcinoma (HCC), whereas 6.6% and 2.1% of PWH without seroclearance developed cirrhosis and HCC, respectively.
Conclusions
Despite long-term tenofovir-containing ART, HBsAg seroclearance was uncommon (0.97% annually) among PWH with HBV coinfection. Birth in the neonatal HBV vaccination era and lower baseline HBsAg level were 2 independent predictors of HBsAg seroclearance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
- Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan.
- Department of Tropical Medicine and Parasitology, National Taiwan University College of Medicine, Taipei, Taiwan.
- Department of Medicine, National Taiwan University Cancer Center, Taipei, Taiwan.
- Infection Control Room, Min-Sheng General Hospital, Taoyuan, Taiwan.
- Department of Laboratory Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
ORCID-Profile: Yu-Shan Huang, Hsin-Yun Sun, Kuan-Yin Lin, Sung-Hsi Huang, Yi-Chia Huang, Guan-Jhou Chen, Chien-Ching Hung
Zitieren
APA
Huang, Y. S., Sun, H. Y., Lin, K. Y., Huang, S. H., Huang, Y. C., Liu, W. D., Chen, G. J., Chen, K. H., Su, L. H., Su, Y. C., Liu, W. C., Chang, S. Y., & Hung, C. C. (2026). Birth in the Neonatal HBV Vaccination Era and Hepatitis B Surface Antigen Seroclearance in People With HIV-1 and HBV Coinfection on Tenofovir-containing Antiretroviral Therapy. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag429
Vancouver
Huang YS, Sun HY, Lin KY, Huang SH, Huang YC, Liu WD, et al. Birth in the Neonatal HBV Vaccination Era and Hepatitis B Surface Antigen Seroclearance in People With HIV-1 and HBV Coinfection on Tenofovir-containing Antiretroviral Therapy. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag429
BibTeX
@article{Huang2026,
author = {Huang, Yu-Shan and Sun, Hsin-Yun and Lin, Kuan-Yin and Huang, Sung-Hsi and Huang, Yi-Chia and Liu, Wang-Da and Chen, Guan-Jhou and Chen, Kai-Hsiang and Su, Li-Hsin and Su, Yi-Ching and Liu, Wen-Chun and Chang, Sui-Yuan and Hung, Chien-Ching},
title = {Birth in the Neonatal HBV Vaccination Era and Hepatitis B Surface Antigen Seroclearance in People With HIV-1 and HBV Coinfection on Tenofovir-containing Antiretroviral Therapy},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciag429}
}
EUVIMED